Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.

Jerath A, Ferguson ND, Cuthbertson B

Intensive Care Med 46 (8) 1563-1566 [2020-08-00; online 2020-06-25]

Hospitals worldwide are experiencing a shortage in essential intravenous sedative medications. This is attributable to high number and high sedative needs of COVID-19 critical care patients with disruption of drug supply chains. Inhaled volatile anesthetic agents are an abundant resource and readily implementable solution for providing ICU sedation. Inhaled volatile agents may also provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. We review the use of volatile agents, and provide a technical overview and algorithm for administering inhaled volatile-based sedation in ICUs.

Type: Review

PubMed 32588067

DOI 10.1007/s00134-020-06154-8

Crossref 10.1007/s00134-020-06154-8

pii: 10.1007/s00134-020-06154-8
pmc: PMC7315695

Publications 9.5.0